PRAGUE--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced the presentation today by Dr. Taghi Manshouri of the University of Texas M. D. Anderson Cancer Center of new mechanism data that further differentiates ZIO-101, a novel organic arsenic, from inorganic arsenic. The mechanism data indicate that certain cancer cells resistant to inorganic arsenic are sensitive to ZIO-101. The presentation was part of the 18th EORTC-NCI-AACR Symposium on “Molecular Targets, and Cancer Therapeutics” meeting held in Prague. ZIO-101 clinical data will be the subject of a separate presentation at this meeting on November 10th.
